{"protocolSection": {"identificationModule": {"nctId": "NCT01234922", "orgStudyIdInfo": {"id": "IRB00014933"}, "secondaryIdInfos": [{"id": "NCI-2010-02043", "type": "OTHER", "domain": "CTRP"}, {"id": "IRB00014933", "type": "OTHER", "domain": "WFUHS IRB"}, {"id": "CCCWFU 98710", "type": "OTHER", "domain": "Wake Forest University Health Sciences"}], "organization": {"fullName": "Wake Forest University Health Sciences", "class": "OTHER"}, "briefTitle": "Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors", "officialTitle": "A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension"}, "statusModule": {"statusVerifiedDate": "2018-07", "overallStatus": "TERMINATED", "whyStopped": "slow accrual", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-02"}, "primaryCompletionDateStruct": {"date": "2013-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-11-03", "studyFirstSubmitQcDate": "2010-11-03", "studyFirstPostDateStruct": {"date": "2010-11-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-12-09", "resultsFirstSubmitQcDate": "2014-12-09", "resultsFirstPostDateStruct": {"date": "2014-12-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-07-30", "lastUpdatePostDateStruct": {"date": "2018-08-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Wake Forest University Health Sciences", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help lower blood pressure.\n\nPURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril, ramipril, or losartan potassium works in treating hypertension in patients with solid tumors.", "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To determine which drug has the greatest effect on Ang-(1-7) levels in cancer patients with hypertension.\n\nSECONDARY OBJECTIVES:\n\nI. To determine the effect of these drugs on levels of Ang II, VEGF, PlGF, and ACE in the same patients.\n\nOUTLINE: Patients are randomized to 1 of 4 treatment arms.\n\n* ARM I: Patients receive oral benazepril hydrochloride once daily on days 1-7.\n* ARM II: Patients receive oral lisinopril once daily on days 1-7.\n* ARM III: Patients receive oral ramipril twice daily on days 1-7.\n* ARM IV: Patients receive oral losartan potassium once daily on days 1-7. In all arms, treatment continues in the absence of unacceptable toxicity."}, "conditionsModule": {"conditions": ["Hypertension", "Unspecified Adult Solid Tumor, Protocol Specific"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 6, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm I", "type": "EXPERIMENTAL", "description": "Patients receive oral benazepril hydrochloride once daily on days 1-7.", "interventionNames": ["Other: laboratory biomarker analysis", "Drug: benazepril hydrochloride"]}, {"label": "Arm II", "type": "EXPERIMENTAL", "description": "Patients receive oral lisinopril once daily on days 1-7.", "interventionNames": ["Drug: lisinopril", "Other: laboratory biomarker analysis"]}, {"label": "Arm III", "type": "EXPERIMENTAL", "description": "Patients receive oral ramipril twice daily on days 1-7.", "interventionNames": ["Other: laboratory biomarker analysis", "Drug: ramipril"]}, {"label": "Arm IV", "type": "EXPERIMENTAL", "description": "Patients receive oral losartan potassium once daily on days 1-7.", "interventionNames": ["Drug: losartan potassium", "Other: laboratory biomarker analysis"]}], "interventions": [{"type": "DRUG", "name": "lisinopril", "description": "Given orally", "armGroupLabels": ["Arm II"], "otherNames": ["Prinivil", "Zestril"]}, {"type": "DRUG", "name": "losartan potassium", "description": "Given orally", "armGroupLabels": ["Arm IV"], "otherNames": ["Cozaar"]}, {"type": "OTHER", "name": "laboratory biomarker analysis", "description": "Correlative studies", "armGroupLabels": ["Arm I", "Arm II", "Arm III", "Arm IV"]}, {"type": "DRUG", "name": "benazepril hydrochloride", "description": "Given orally", "armGroupLabels": ["Arm I"], "otherNames": ["benazepril HCl", "CGS14824A", "Lotensin"]}, {"type": "DRUG", "name": "ramipril", "description": "Given orally", "armGroupLabels": ["Arm III"], "otherNames": ["Altace"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter", "timeFrame": "7 days post-baseline"}], "secondaryOutcomes": [{"measure": "Change in Ang II, VEGF, PlGF, and ACE Levels", "timeFrame": "1 week"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed solid tumor malignancy AND hypertension, defined as a systolic pressure \\> 130 OR a diastolic pressure \\> 80\n* Patients cannot be on active chemotherapy or radiation therapy; start of treatment with ACE-I or ARB must occur at least four weeks after the last dose of chemotherapy or radiation therapy\n* Creatinine \\< 2.5\n* Potassium \\< ULN\n* Ability to understand and the willingness to sign a written informed consent document\n* HIV positive patients are eligible to participate in this study\n\nExclusion Criteria:\n\n* Patients who are pregnant or nursing due to significant risk to the fetus/infant\n* Patients who are unable to take oral medications\n* Patients who are currently taking an ACE-Inhibitor or ARB", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "William Petty", "affiliation": "Wake Forest University Health Sciences", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Wake Forest University Health Sciences", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Protocol was closed early due to slow accrual", "groups": [{"id": "FG000", "title": "Arm I", "description": "Patients receive oral benazepril hydrochloride once daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nbenazepril hydrochloride: Given orally"}, {"id": "FG001", "title": "Arm II", "description": "Patients receive oral lisinopril once daily on days 1-7.\n\nlisinopril: Given orally\n\nlaboratory biomarker analysis: Correlative studies"}, {"id": "FG002", "title": "Arm III", "description": "Patients receive oral ramipril twice daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nramipril: Given orally"}, {"id": "FG003", "title": "Arm IV", "description": "Patients receive oral losartan potassium once daily on days 1-7.\n\nlosartan potassium: Given orally\n\nlaboratory biomarker analysis: Correlative studies"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Arm I", "description": "Patients receive oral benazepril hydrochloride once daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nbenazepril hydrochloride: Given orally"}, {"id": "BG001", "title": "Arm II", "description": "Patients receive oral lisinopril once daily on days 1-7.\n\nlisinopril: Given orally\n\nlaboratory biomarker analysis: Correlative studies"}, {"id": "BG002", "title": "Arm III", "description": "Patients receive oral ramipril twice daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nramipril: Given orally"}, {"id": "BG003", "title": "Arm IV", "description": "Patients receive oral losartan potassium once daily on days 1-7.\n\nlosartan potassium: Given orally\n\nlaboratory biomarker analysis: Correlative studies"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "6"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "4"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "2"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.1", "spread": "0"}, {"groupId": "BG001", "value": "68.8", "spread": "0"}, {"groupId": "BG002", "value": "62.2", "spread": "1.45"}, {"groupId": "BG003", "value": "65.5", "spread": "6.15"}, {"groupId": "BG004", "value": "61.7", "spread": "8.19"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "4"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "6"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "6"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Picogram/milliliter", "timeFrame": "7 days post-baseline", "groups": [{"id": "OG000", "title": "Arm I", "description": "Patients receive oral benazepril hydrochloride once daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nbenazepril hydrochloride: Given orally"}, {"id": "OG001", "title": "Arm II", "description": "Patients receive oral lisinopril once daily on days 1-7.\n\nlisinopril: Given orally\n\nlaboratory biomarker analysis: Correlative studies"}, {"id": "OG002", "title": "Arm III", "description": "Patients receive oral ramipril twice daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nramipril: Given orally"}, {"id": "OG003", "title": "Arm IV", "description": "Patients receive oral losartan potassium once daily on days 1-7.\n\nlosartan potassium: Given orally\n\nlaboratory biomarker analysis: Correlative studies"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.25", "spread": "0"}, {"groupId": "OG001", "value": "33.67", "spread": "0"}, {"groupId": "OG002", "value": "6.685", "spread": "10.815"}, {"groupId": "OG003", "value": "5.045", "spread": "5.275"}]}]}]}, {"type": "SECONDARY", "title": "Change in Ang II, VEGF, PlGF, and ACE Levels", "populationDescription": "Data were not analyzed due to insufficient accrual to the study and lack of statistical power.", "reportingStatus": "POSTED", "timeFrame": "1 week", "groups": [{"id": "OG000", "title": "Arm I", "description": "Patients receive oral benazepril hydrochloride once daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nbenazepril hydrochloride: Given orally"}, {"id": "OG001", "title": "Arm II", "description": "Patients receive oral lisinopril once daily on days 1-7.\n\nlisinopril: Given orally\n\nlaboratory biomarker analysis: Correlative studies"}, {"id": "OG002", "title": "Arm III", "description": "Patients receive oral ramipril twice daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nramipril: Given orally"}, {"id": "OG003", "title": "Arm IV", "description": "Patients receive oral losartan potassium once daily on days 1-7.\n\nlosartan potassium: Given orally\n\nlaboratory biomarker analysis: Correlative studies"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events were collected for 7 days after dosing", "eventGroups": [{"id": "EG000", "title": "Arm I", "description": "Patients receive oral benazepril hydrochloride once daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nbenazepril hydrochloride: Given orally", "seriousNumAffected": 0, "seriousNumAtRisk": 1, "otherNumAffected": 1, "otherNumAtRisk": 1}, {"id": "EG001", "title": "Arm II", "description": "Patients receive oral lisinopril once daily on days 1-7.\n\nlisinopril: Given orally\n\nlaboratory biomarker analysis: Correlative studies", "seriousNumAffected": 0, "seriousNumAtRisk": 1, "otherNumAffected": 1, "otherNumAtRisk": 1}, {"id": "EG002", "title": "Arm III", "description": "Patients receive oral ramipril twice daily on days 1-7.\n\nlaboratory biomarker analysis: Correlative studies\n\nramipril: Given orally", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 1, "otherNumAtRisk": 2}, {"id": "EG003", "title": "Arm IV", "description": "Patients receive oral losartan potassium once daily on days 1-7.\n\nlosartan potassium: Given orally\n\nlaboratory biomarker analysis: Correlative studies", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 2, "otherNumAtRisk": 2}], "otherEvents": [{"term": "Hemoglobin", "organSystem": "Investigations", "sourceVocabulary": "CTC version 3", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CTCAE (3.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}]}, {"term": "hyperglycemia", "organSystem": "Investigations", "sourceVocabulary": "CTCAE (3.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CTCAE (3.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}]}, {"term": "Pain, Chest", "organSystem": "General disorders", "sourceVocabulary": "CTCAE (3.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}]}, {"term": "lymphopenia", "organSystem": "Investigations", "sourceVocabulary": "CTCAE (3.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}]}, {"term": "vomitting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CTCAE (3.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}]}, {"term": "nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "CTCAE (3.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}]}, {"term": "hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "CTCAE (3.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 2}]}, {"term": "fatigue", "organSystem": "General disorders", "sourceVocabulary": "CTCAE (3.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 1}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 2}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "William J. Petty, MD", "organization": "Wake Forest Baptist Health", "email": "wpetty@wakehealth.edu", "phone": "336-716-3313"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000017257", "term": "Ramipril"}, {"id": "D000017706", "term": "Lisinopril"}, {"id": "C000044946", "term": "Benazepril"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000002316", "term": "Cardiotonic Agents"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M21701", "name": "Losartan", "asFound": "Gradual", "relevance": "HIGH"}, {"id": "M19924", "name": "Lisinopril", "asFound": "Amplitude", "relevance": "HIGH"}, {"id": "M19553", "name": "Ramipril", "asFound": "Mandibular", "relevance": "HIGH"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M223594", "name": "Benazepril", "asFound": "Iliac crest", "relevance": "HIGH"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M5572", "name": "Cardiotonic Agents", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}